Vaccine-Induced T-Cell and Antibody Responses at 12 Months after Full Vaccination Differ with Respect to Omicron Recognition
More than a year after the first vaccines against the novel SARS-CoV-2 were approved, many questions still remain about the long-term protection conferred by each vaccine. How long the effect lasts, how effective it is against variants of concern and whether further vaccinations will confer addition...
Main Authors: | Franz Mai, Johann Volzke, Emil C. Reisinger, Brigitte Müller-Hilke |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/10/9/1563 |
Similar Items
-
Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2
by: Brigitte Müller-Hilke, et al.
Published: (2022-02-01) -
NVX-CoV2373 induces humoral and cellular immune responses that are functionally comparable to vector and mRNA-based vaccines
by: Franz Mai, et al.
Published: (2024-03-01) -
Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination
by: Jaeeun Yoo, et al.
Published: (2023-10-01) -
The importance of booster vaccination in the context of Omicron wave
by: Zichun Wei, et al.
Published: (2022-09-01) -
Past Life and Future Effects—How Heterologous Infections Alter Immunity to Influenza Viruses
by: Aisha Souquette, et al.
Published: (2018-05-01)